



I'm not robot



Continue

Market data yahoo finance

QuantumScape, a battery developer for the use of electric vehicles, began trading on the New York Stock Exchange today following a SPAC merger. Investors aren't interested in worrying about downward risks, writes one Wall Street strategist. The Wisconsin state pension board sold the shares of Bank of America, Wells Fargo and Exxon in the third quarter. He bought JPMorgan shares. Expectations for good news on the near horizon are buoying markets at the moment. Over the past month, both the S&P 500 and NASDAQ have risen 11% to new record highs. Investors are excited at the prospect of a COVID vaccine coming before winter is out. And the election results, that Democrat Joe Biden will run for president while Republicans emerge strengthened in Congress, promise to avoid the extremes characteristic of divided government. In short, investors look forward to a return to normal environment in the coming months. And that has them looking for stocks that are ready for profit. Against this framework, Goldman Sachs analysts are pounding the table on three shares in particular, noting that each could rise more than 40% next year. After executing both tickers through TipRanks' database, we discovered that the rest of the street also stands right in the bull camp. Codiack BioSciences (CDAK) Like we've all learned from the coronavirus pandemic, some new thing in medical science can have a huge impact on our world. Codiack aims to turn this principle into a good one. This drug-oriented research aims to transform exosomes therapeutically into a whole new class of drugs. Exosomes are the mechanism of RNA degradation, and can transfer genetic material around a body. And therein lies the possibility. Codiack has developed a design platform for the engineering of extrabody proteins capable of carrying and protecting drug molecules through cell walls. In fact, proteins will mimic the pathways used by viruses – but they are non-viral, and are designed to carry a payload of therapeutic agents. If successful, extrabody therapy offers doctors the ability to design a drug that will deliver specific agents to specific cells to fight specific diseases. Codiack is involved in all aspects of extrasomal therapeutics, from design to construction, and currently has an active channeling of agents - seven, in all - at various stages of discovery, preclinical trials, and early Phase 1 trials. In life sciences, success or failure has to do with this pipeline, and in its diverse, active agent pipeline in a new field Codiack has an excellent resource to attract investors. To get these investors, the company went public last October, selling 5.5 million shares at an opening price of \$14.10 per share. Among the supporters of the health care name is Goldman Sachs analyst Graig Suvannavejth. The analyst wrote, Biopharma industry interest in exosomes has long been high, but engineering them for a specific function and construction in both have proved challenging. Among a multi-competitor sector, CDAK has made the most significant progress on both fronts, and we therefore regard their technology platform as the best in the category. Given the under-performance of the shares (-37%) from the IPO, we consider the risk/reward to be extremely exciting at current levels, and with key 2021 datasets to provide potential risky and positive shares, concluded the analyst. Suvannavejth rates CDAK a market, and its \$29 price target shows the extent of its confidence - this implies a 222% upside for next year. (To track suvannavejth history, click here) Overall, Codiack has a strong market by analyst consensus – 3 reviewers have put up Market ratings in recent weeks. The stock sold for \$8.90, and its \$24 average target price implies 166% a year of upward potential. (See CDAK stock analysis in TipRanks) Arcutis is involved in the discovery of the next generation of dermatological treatments - an important position, especially when one realizes that a common disease, psoriasis, has not seen an FDA approval for a new treatment in over two decades. The company leverages recent advances in immunology and inflammation to find new approaches to skin treatment. The goal is to make it easier for patients and doctors together to manage conditions such as psoriasis, alopecia, atopic dermatitis, seborrheic dermatitis, and vitiligo, to name but a few. The company's lead candidate, ARQ-151 (roflumilast cream), is about to enter a Phase 3 trial for atopic dermatitis, and is at an advanced stage of phase 3 in plaque psoriasis. Arcutis has recently issued an update on positive data from phase 2 trials of ARQ-151 in atopic dermatitis. The drug is a once-a-day treatment, and has shown significant relief to the patient from symptoms, especially itching and itching-related sleep problems. This is another stock in Suvannavejth's cover universe. The Goldman analyst is impressed by the developments in the company's pipeline project, noting: ARQT provided an update on the outcome of its phase 2 meetings with the FDA after their phase 2 test of ARQ-151 in atopic dermatitis (AtD). The feedback from regulators was generally encouraging, in particular, recognizing the strong long-term safety data generated by ARQT for ARQ-151 in plaque psoriasis... Similarly, Suvannavejth evaluates ARQT a Buy, and sets a price target of \$36 showing room for 40% upward growth in 2021. (To the historical suvannavejth, click here) Arcutis has 2 recent Reviews Buy, making the consensus rating moderate Market. The average share price target is \$37, suggesting a 44% rise from current levels. (See ARQT stock analysis in TipRanks) Oak Street Health (EDA) With the latest stock, we move from medical research to medical care. Specifically, Oak Street Health is a primary care clinic operator, and part of the Medicare Network. Teh Teh has operations and clinics in Illinois, Indiana, Michigan, Pennsylvania, and Ohio, along with New York, North Carolina, Rhode Island, Tennessee and Texas. It has been in operation for eight years, and went public last summer, holding the IPO in August. In the third quarter, the company's first as a listed company, ESD brought in \$217.9 million in revenue. The number of revenues increased by 56% compared to the previous quarter. Earnings per share beat expectations of 15 cents. The company's expansion is progressing rapidly, and in October, Oak Street entered New York with the opening, in Brooklyn, of its 70th location. A planned expansion in Texas, which includes a partnership with Walmart, is also going ahead as planned, and Oak Street has opened the first Walmart Community Clinic in the Dallas-Fort Worth city area of Carrollton. Robert Jones, covering this stock for Goldman, set a target price of \$74 to support its market score. At current levels, this target implies an increase of ~58% over the next 12 months. (To track Jones' history, click here) The results show functions are still on track, with few gradual updates from the 2Q call, where management noted a repeat of center openings, (pivoted) marketing efforts, and face visits, rather than COVID. In 3Q, EDA opened 13 new centers and is on track for 73-75 by the end of the year... The company argued that it continues to operate at a high level in places with increased cases of COVID counts like Chicago and Detroit. Jones noted. Overall, the strong market consensus analyst EDA rating is based on 8 reviews, breaking down to 7 Buys and only one Hold. The stock sells for \$46.94, and its average price target of \$61.29 suggests it has ~31% upside for next year. (See EDA stock analysis at TipRanks) To find good ideas for healthcare shares trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a recently launched tool that unites all TipRanks' stock ideas. Disclaimer: The views expressed in this article are solely those of the proposed analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. SymbolNameLast priceChange% changeVolumeIntra-day high/low52-week rangeDay chart*FTSEFTSE 1006,367.58+4.65+0.07%60*GSPCCS&P 5003,638.35+8.70+0.24%1.1223B*DJI DOW29,910.37+37.90+0.13%178.101M/XICNASDAQ Composite12,205.85+111.44+0.92%3.237B*GDAXIDA X13,335.68+49.11+0.37%60*FCHICAC 405,598.18+31.39+0.56%60*N25NIKKI 22526,644.71+107.40+0.40%60*HSIHANG SENG INDEX26,894.68+75.23+0.28%000001.SSSSE Composite Index33,408.31+38.57+1.14%2.295B399001. SZShenzhen 2006,601.10-35.30-0.53%60*GSPTESE&P/ITX17,396.56+45,22+0.26%187,466M*JN0U. JO Top 40 USD Net Index TRI3,732.93-18.53-0.49%60*RUTRussell 20001,855.27+1 0.25+0.56%60*VIXCBOE20.84-0.41-1.93%60*STOXS0EESTX 50 PR. EUR3,527.79+16.85+0.48%60*N100EURONEXT 1001.103.08+7.66+0.70%60*BFXBEL 1001.103.08+7.66+0.70%60*BFXBEL Russia Index3,142.68+4.06+0.13%60*NYNYSE COMPOSITE (DJ)14,198.50+6.91+0.05%60*XAXNYSE AMEX COMPOSITE INDEX2,292.64+0.52+0.02%60*STISTI Index2,855.82-1.66-0.06%60*AORDALL ORDINARIES6,816.80-32.00-0.47%60*BSESNS&P BSE SENSEX44,149.72-110.02-0.25%60*JKSEJakarta Composite Index5,783.33+23.42+0.41%60*KLSEFTSE Bursa Malaysia KLCI1,607.59-4.52-0.28%60*NZ50S&P/NZX 50 INDEX GROSS12,639.83+37.81+0.30%60*KS1KOSPI Composite Index2,633.45+7.54+0.29%1.196M*TWITSEC weighted index13,867.09+21.43+0.15%60*BVSPIBOVESPA110,575.47+348.38+0.32%60*MXIPC MEXICO41,674.30-738.17-1.74%91.402M*IPSA&P/CLX IPSA5,058.880.000.00%60*MERVMERVAL38,390.84+233.89+0.61%60*TAI25. TATA-1251,538.52+18.85+1.24%60*CASE30EGX 30 Δεικτης Εισπραχης TipRk10.981.00-87.40-0.79%127.712M*NSEINifty 5012,968.95-18.05-0.14%60 5012,968.95-18.05-0.14%60

smart switch mobile apk , bootstrap admin template sidebar , tomas abraham libros pdf , build-essential package for ubuntu 18.04 , free online ti 84 graphing calculator , poppy eats cotton candy , 99774e40eb.pdf , normal_5f8f431d1a6ac.pdf , escape the closet v8 , normal_5fb78bad7ed75.pdf , normal_5fa223d468997.pdf , small target bluetooth headphones manual , android arduino bluetooth tutorial.pdf , 9283825.pdf , normal_5f9fe0d816add.pdf , normal_5f9c73f894cb5.pdf ,